Leadman(SZ:300289)2023-04-20 16:00Financial Performance - Revenue for Q1 2023 was CNY 108,150,382.74, a decrease of 43.55% compared to CNY 191,578,138.79 in the same period last year[5] - Net profit attributable to shareholders was CNY 8,296,310.96, down 31.49% from CNY 12,109,083.40 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.0153, a decrease of 30.45% from CNY 0.022 in the same period last year[5] - The total comprehensive income for Q1 2023 was CNY 10,109,371.69, compared to CNY 18,442,533.26 in Q1 2022, reflecting a decrease of approximately 45.0%[28] - Net profit for Q1 2023 was CNY 10,109,371.69, a decline of 45.0% compared to CNY 18,442,533.26 in Q1 2022[27] Cash Flow - Net cash flow from operating activities increased by 535.02% to CNY 27,508,461.89, compared to CNY 4,331,880.00 in the previous year[5] - Cash inflows from operating activities totaled CNY 142,616,871.69, a decrease from CNY 248,793,538.36 in the previous year, reflecting a decline of about 42.6%[30] - Cash outflows from operating activities were CNY 115,108,409.80, down from CNY 244,461,658.36, resulting in a net cash flow from operating activities of CNY 27,508,461.89, compared to CNY 4,331,880.00 in the previous year[31] - The net cash flow from investing activities improved by 87.03%, amounting to CNY -41,878,200.00, compared to CNY -322,868,300.00 in the same period last year[14] - The net cash flow from financing activities was CNY -2,782,067.94, an improvement from CNY -4,452,419.68 in the previous year[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,941,239,161.02, a decrease of 2.80% from CNY 1,997,134,641.92 at the end of the previous year[5] - Total liabilities decreased to CNY 150,662,386.21 in Q1 2023 from CNY 216,667,238.80 in the same period last year[25] - Cash and cash equivalents at the end of the reporting period were RMB 781.66 million, down from RMB 798.81 million at the beginning of the year[23] - The company reported a decrease in accounts receivable to CNY 165,515,052.40 from CNY 184,081,260.63 year-over-year, indicating improved collection efforts[25] Business Segments - The in vitro diagnostic reagent business generated RMB 89.06 million in revenue, a decline of 46.15%, accounting for 82.34% of total revenue[18] - The diagnostic instruments (including accessories and consumables) segment reported revenue of RMB 4.83 million, down 61.96%, representing 4.47% of total revenue[18] Research and Development - Research and development expenses for Q1 2023 amounted to CNY 8,464,282.68, a decrease of 7.3% from CNY 9,130,522.32 in Q1 2022[27] - The company has four new products under registration and one new biochemical diagnostic reagent product has obtained registration certification[18] - The company added one new utility model patent and one new invention patent application during the reporting period[19] Shareholder Activities - The company completed a share buyback plan, with Vice President Ding Yaoliang purchasing 1,140,000 shares for a total of RMB 6.99 million[20] - The company paid a total of RMB 39.35 million as the remaining transfer price for acquiring a 51% stake in Guotuo (Xiamen) Cold Chain Logistics Co., Ltd.[21] Other Information - The company reported a 100% decrease in accounts payable, dropping to CNY 0.00 from CNY 1,967,200.00 due to the payment of matured acceptance bills[10] - The company's weighted average return on equity decreased to 0.48% from 0.66% year-on-year[5] - The company's total equity attributable to shareholders increased by 0.48% to CNY 1,735,601,004.17 from CNY 1,727,304,693.21 at the end of the previous year[5] - The Q1 2023 report was not audited, indicating that the figures are preliminary and subject to change[32]